Nicotine dependence - Human and animal studies, current pharmacotherapies and future perspectives

Pharmacological Reports

Volumn 61, Issue 6, 2009, Pages 957-965

  Zaniewska, Magdalena ^a   Przegaliński, Edmund ^a   Filip, Małgorzata ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Clinical trials; Drug discrimination; Nicotine; Nicotine pharmacotherapy; Rat; Reinstatement of seeking behavior; Self administration; Sensitization

Indexed keywords

(3 AMINO 2 HYDROXYPROPYL)METHYLPHOSPHINIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; ALLERGON; AMFEBUTAMONE; ANABASINE; BACLOFEN; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CGP 44532; CIGARETTE SMOKE; CLONIDINE; COTININE; CYTISINE; HARMAN; IPOREL; MOCLOBEMIDE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NALTREXONE; NICOTINE; NICOTINE GUM; NORNICOTINE; NORTRIPTYLINE; PHOSPHINIC ACID DERIVATIVE; REBOXETINE; RIMONABANT; SELEGILINE; TOBACCO SMOKE; UNCLASSIFIED DRUG; VARENICLINE;

ACUTE TOXICITY; ALERTNESS; AMNESIA; ANHEDONIA; ANXIETY; BINDING AFFINITY; BRADYCARDIA; CLINICAL EFFECTIVENESS; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; CONVULSION; DEATH; DEPRESSION; DIARRHEA; DISEASE MODEL; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DYSPHORIA; ESCAPE BEHAVIOR; FATIGUE; GASTROINTESTINAL SYMPTOM; GROOMING; HEAD TWITCH; HEADACHE; HUMAN; HYPOTENSION; INCREASED APPETITE; INSOMNIA; IRRITABILITY; JUMPING; LEARNING; MASTICATION; MEMORY; MENTAL CONCENTRATION; MUSCLE RELAXATION; MUSCLE SPASM; MYALGIA; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PALLOR; PHOTOPHOBIA; PSYCHOANALYTIC THEORY; REFLEX; RESPIRATION DEPRESSION; REVIEW; SCRATCHING; SMOKING CESSATION; SOMNOLENCE; STOMACH DISEASE; STOMACH SECRETION; SUSTAINED DRUG RELEASE; SWEATING; TACHYCARDIA; TACHYPNEA; TOBACCO DEPENDENCE; TREATMENT FAILURE; TREMOR; VASOCONSTRICTION; WEIGHT GAIN; WET DOG SHAKES; WITHDRAWAL SYNDROME; XEROSTOMIA; YAWNING;

EID: 76049130645     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70157-4     Document Type: Review

References (78)

1. Andersson C, Wennström P, Gry J: Nicotine alkaloids in Solanaceous food plants. TemaNord, 2003, 531, 1-37.
2. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN et al.: Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry, 1995, 56, 395-401.
3. Balfour DJ: Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence. Curr Drug Targets CNS Neurol Disord, 2002, 1, 413-421.
4. Berrettini WH, Lerman CE: Pharmacotherapy and pharmacogenetics of nicotine dependence. Am J Psychiatry, 2005, 162, 1441-1451.
5. Biała G, Budzyńska B, Kruk M: Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice. Pharmacol Rep, 2005, 57, 755-760.
6. Biała G, Kruk M: Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep, 2009, 61, 236-244.
7. Biernat M: The truth about nicotine (Polish). Articles wiki: http://bioinfo.mol.uj.edu.pl/articles/Biernat05, 2006.
8. Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, 2007, (1), CD006103.
9. Calabresi P, Di Filippo M: ACh/dopamine crosstalk in motor control and reward: a crucial role for alpha 6-containing nicotinic receptors? Neuron, 2008, 60, 4-7.
10. Carroll IF, Yokota Y, Wei M, Lee JR, Brieaddy LE, Burgess JP, Navarro HA et al.: Synthesis, nicotinic acetylcholine receptor binding, and pharmacological properties of 3′-(substituted phenyl)deschloroepibatidine analogs. Bioorg Med Chem, 2008, 16, 746-754.
11. Chae Y, Yeom M, Han JH, Park HJ, Hahm DH, Shim I, Lee HS et al.: Effect of acupuncture on anxiety-like behavior during nicotine withdrawal and relevant mechanisms. Neurosci Lett, 2008, 430, 98-102.
12. Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Lena C, Clementi F et al.: Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci, 2003, 23, 7820-7829.
13. Cheeta S, Irvine E, File SE: Social isolation modifies nicotine's effects in animal tests of anxiety. Br J Pharmacol, 2001, 132, 1389-1395.
14. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A: Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet, 2007, 370, 1706-1713.
15. Clarke PB, Kumar R: The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br J Pharmacol, 1983, 78, 329-337.
16. 1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav, 2005, 81, 387-395.
17. Corrigall WA, Coen KM: Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology, 1989, 99, 473-478.
18. Cruz FC, Delucia R, Planeta CS: Differential behavioral and neuroendocrine effects of repeated nicotine in adolescent and adult rats. Pharmacol Biochem Behav, 2005, 80, 411-417.
19. Cryan JF, Gasparini F, van Heeke G, Markou A: Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug Discov Today, 2003, 8, 1025-1034.
20. Cummings KM: Present and future methods for the treatment of nicotine dependence (Polish). Medycyna po dyplomie, 2007, 16, 28-40.
21. Dalsgareth OJ, Hansen NC, Sřes-Petersen U, Evald T, Hřegholm A, Barber J, Vestbo J: A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob Res, 2004, 6, 55-61.
22. Damaj MI, Welch SP, Martin BR: Nicotine-induced antinociception in mice: role of G-proteins and adenylate cyclase. Pharmacol Biochem Behav, 1994, 48, 37-42.
23. Davenport KE, Houdi AA, Van Loon GR: Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci Lett, 1990, 113, 40-46.
24. Dhatt RK, Gudehithlu KP, Wemlinger TA, Tejwani GA, Neff NH, Hadjiconstantinou M: Preproenkephalin mRNA and methionine-enkephalin content are increased in mouse striatum after treatment with nicotine. J Neurochem, 1995, 64, 1878-1883.
25. DiFranza JR, Savageau JA, Rigotti NA, Fletcher K, Ockene JK, McNeill AD, Coleman M et al.: Development of symptoms of tobacco dependence in youths: 30 month follow up data from the DANDY study. Tob Control, 2002, 11, 228-235.
26. EMEA: Guideline on the development of medicinal products for the treatment of nicotine dependence. 2007.
27. FDA Consum: The FDA approves new drug for smoking cessation. 2006, 40, 29.
28. Fowler CD, Arends MA, Kenny PJ: Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice. Behav Pharmacol, 2008, 19, 461-484.
29. Garwood CL, Potts LA: Emerging pharmacotherapies for smoking cessation. Am J Health Syst Pharm, 2007, 64, 1693-1698.
30. George TP, O'Malley SS: Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci, 2004, 25, 42-48.
31. George TP, Weinberger AH: Monoamine oxidase inhibition for tobacco pharmacotherapy. Clin Pharmacol Ther, 2008, 83, 619-621.
32. Green TA, Cain ME, Thompson M, Bardo MT: Environmental enrichment decreases nicotine-induced hyperactivity in rats. Psychopharmacology, 2003, 170, 235-241.
33. Harvey DM, Yasar S, Heishman SJ, Panlilio LV, Henningfield JE, Goldberg SR: Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology, 2004, 175, 134-142.
34. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML: Pharmacotherapy for nicotine dependence. CA Cancer J Clin, 2005, 55, 281-299.
35. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW: Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry, 1991, 48, 52-59.
36. Hughes JR, Stead LF, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev, 2007, (1), CD000031.
37. Jones S, Sudweeks S, Yakel JL: Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci, 1999, 22, 555-561.
38. Kalamida D, Poulas K, Avramopoulou V, Fostieri E, Lagoumintzis G, Lazaridis K, Sideri A et al.: Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. FEBS J, 2007, 274, 3799-3845.
39. Kalman D: The subjective effects of nicotine: methodological issues, a review of experimental studies, and recommendations for future research. Nicotine Tob Res, 2002, 4, 25-70.
40. Kenny PJ, Markou A: Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems. J Neurosci, 2005, 25, 6208-6212.
41. Kenny PJ, Markou A: Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav, 2001, 70, 531-549.
42. Kostowski W: Drug addiction: theories and hypotheses (Polish). Psychiatria, 2005, 2, 61-76.
43. Le Foll B, Goldberg SR: Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends Pharmacol Sci, 2005, 26, 287-293.
44. Le Foll B, Goldberg SR: Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol, 2009, 192, 335-367.
45. Le Foll B, Goldberg SR: Nicotine induces conditioned place preferences over a large range of doses in rats. Psychopharmacology, 2005, 178, 481-492.
46. Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV: Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep, 2009, 61, 217-224.
47. 1 agonist and antagonist drugs. Psychopharmacology, 1996, 127, 25-30.
48. Levin ED, McClernon FJ, Rezvani AH: Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology, 2006, 184, 523-539.
49. Malin DH: Nicotine dependence: studies with a laboratory model. Pharmacol Biochem Behav, 2001, 70, 551-559.
50. Marano G, Ramirez A, Mori I, Ferrari AU: Sympathectomy inhibits the vasoactive effects of nicotine in conscious rats. Cardiovasc Res, 1999, 42, 201-205.
51. Markou A: Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci, 2008, 363, 3159-3168.
52. Matta SG, Fu Y, Valentine JD, Sharp BM: Response of the hypothalamo-pituitary-adrenal axis to nicotine. Psychoneuroendocrinology, 1998, 23, 103-113.
53. Maurer P, Bachmann MF: Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs, 2007, 16, 1775-1783.
54. Mihailescu S, Palomero-Rivero M, Meade-Huerta P, Maza-Flores A, Drucker-Colín R: Effects of nicotine and mecamylamine on rat dorsal raphe neurons. Eur J Pharmacol, 1998, 360, 31-36.
55. Mihalak KB, Carroll FI, Luetje CW: Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol, 2006, 70, 801-805.
56. Miller DK, Wilkins LH, Bardo MT, Crooks PA, Dwoskin LP: Once weekly administration of nicotine produces long-lasting locomotor sensitization in rats via a nicotinic receptor-mediated mechanism. Psychopharmacology, 2001, 156, 469-476.
57. Myers MG, Kelly JF: Cigarette smoking among adolescents with alcohol and other drug use problems. Alcohol Res Health, 2006, 29, 221-227.
58. NIDA Research Report: Nicotine addiction. 1998.
59. Nowakowska E, Kus K, Florek E, Czubak A, Jodynis-Liebert J: The influence of tobacco smoke and nicotine on antidepressant and memory-improving effects of venlafaxine. Hum Exp Toxicol, 2006, 25, 199-209.
60. Ouagazzal AM, Kenny PJ, File SE: Modulation of behaviour on trials 1 and 2 in the elevated plus-maze test of anxiety after systemic and hippocampal administration of nicotine. Psychopharmacology, 1999, 144, 54-60.
61. PDSP database: http://pdsp.med.unc.edu/indexR.html.
62. Picciotto MR: Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci, 2003, 24, 493-499.
63. Picciotto MR, Caldarone BJ, King SL, Zachariou V: Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology, 2000, 22, 451-465.
64. Pogocki D, Ruman T, Danilczuk M, Danilczuk M, Celuch M, Wałajtys-Rode E: Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders. Eur J Pharmacol, 2007, 563, 18-39.
65. Popik P, Krawczyk M, Kos T, Nalepa I, Kowalska M, Witarski T, Antkiewicz-Michaluk L, Vetulani J: Nicotine produces antidepressant-like actions: Behavioral and neurochemical evidence. Eur J Pharmacol, 2005, 515, 128-133.
66. Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y, CIRRUS Study Group: A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction, 2009, 104, 266-276.
67. Rosecrans JA, Villanueva HF: Discriminative stimulus properties of nicotine: mechanisms of transduction. NIDA Res Monogr, 1991, 116, 101-116.
68. 3H]acetylcholine on catecholamine and serotonin axons in brain. J Neurochem, 1984, 42, 1495-1498.
69. Seth P, Cheeta S, Tucci S, File SE: Nicotinic-serotonergic interactions in brain and behaviour. Pharmacol Biochem Behav, 2002, 71, 795-805.
70. Siemińska A: Genetic factors influencing tobacco dependence (Polish). Alergia Astma Immunologia, 2005, 10, 69-73.
71. Suemaru K, Yasuda K, Cui R, Li B, Umeda K, Amano M, Mitsuhashi H et al.: Antidepressant-like action of nicotine in forced swimming test and brain serotonin in mice. Physiol Behav, 2006, 88, 545-549.
72. Terry AVJr, Clarke MS: Nicotine stimulation of nerve growth factor receptor expression. Life Sci, 1994, 55, 91-98.
73. Touiki K, Rat P, Molimard R, Chait A, de Beaurepaire R: Harmane inhibits serotonergic dorsal raphe neurons in the rat. Psychopharmacology, 2005, 182, 562-569.
74. US DHHS: The Health Consequences of Smoking: Nicotine Addiction: A Report of the Surgeon General. 1988.
75. Vezina P, McGehee DS, Green WN: Exposure to nicotine and sensitization of nicotine-induced behaviors. Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31, 1625-1638.
76. West R, Baker CL, Cappelleri JC, Bushmakin AG: Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology, 2008, 197, 371-377.
77. Wonnacott S, Barik J: Nicotinic ACh receptors. Tocris Bioscience Scientific Review Series, 2007, 28, 1-18.
78. 2 receptor-targeting ligands and nicotine: locomotor activity studies in rats. Synapse, 2009, 63, 653-661.